Article
Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms.
Circulation - 5 Jan 2010
Sofat Reecha, Hingorani Aroon D, Smeeth Liam, Humphries Steve E, Talmud Philippa J, Cooper Jackie, Shah Tina, Sandhu Manjinder S, Ricketts Sally L, Boekholdt S Matthijs, Wareham Nicholas, Khaw Kay Tee, Kumari Meena, Kivimaki Mika, Marmot Michael, Asselbergs Folkert W, van der Harst Pim, Dullaart Robin P F, Navis Gerjan, van Veldhuisen Dirk J, Van Gilst Wiek H, Thompson John F, McCaskie Pamela, Palmer Lyle J, Arca Marcello, Quagliarini Fabiana, Gaudio Carlo, Cambien François, Nicaud Viviane, Poirer Odette, Gudnason Vilmundur, Isaacs Aaron, Witteman Jacqueline C M, van Duijn Cornelia M, Pencina Michael, Vasan Ramachandran S, D'Agostino Ralph B, Ordovas Jose, Li Tricia Y, Kakko Sakari, Kauma Heikki, Savolainen Markku J, Kesäniemi Y Antero, Sandhofer Anton, Paulweber Bernhard, Sorli Jose V, Goto Akimoto, Yokoyama Shinji, Okumura Kenji, Horne Benjamin D, Packard Chris, Freeman Dilys, Ford Ian, Sattar Naveed, McCormack Valerie, Lawlor Debbie A, Ebrahim Shah, Smith George Davey, Kastelein John J P, Deanfield John, Casas Juan P
Abstract excerpt
BACKGROUND: Cholesteryl ester transfer protein (CETP) inhibitors raise high-density lipoprotein (HDL) cholesterol, but torcetrapib, the first-in-class inhibitor tested in a large outcome trial, caused an unexpected blood pressure elevation and increased cardiovascular events. Whether the hyperten...
Read the complete abstract on PubMed